Opportunity Information: Apply for RFA HL 24 008
The NIH funding opportunity RFA-HL-24-008, titled "The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)," is focused on clarifying how insufficient sleep and circadian rhythm disruption influence the biology of Type 1 Diabetes (T1D), especially in ways that shape glycemic control and cardiovascular risk. The central aim is not simply to document that sleep problems occur in T1D, but to dig into clinically meaningful mechanisms that explain how sleep and circadian factors drive metabolic and cardiovascular changes, affect disease progression over time, and potentially alter how patients respond to treatment. The broader payoff NIH is looking for is evidence that can support practical sleep- or circadian-based strategies that ultimately improve outcomes for people living with T1D and reduce related cardiovascular complications.
This R01 emphasizes mechanism-focused, clinically relevant research at the intersection of sleep/circadian science, diabetes, and cardiovascular biology. Applications are expected to bring together multidisciplinary expertise, for example by integrating sleep and circadian measurement and biology with endocrinology/diabetes management and cardiovascular phenotyping. The opportunity is designed to support work that gets closer to explaining "how and why" sleep deficiency and circadian disruption matter in T1D, rather than only showing "whether" they are associated with outcomes. Because the notice is labeled "Clinical Trial Optional," applicants may propose studies that include a clinical trial component if it is scientifically justified, but a clinical trial is not required. The key is that any human research should be tightly connected to mechanistic questions with clear relevance to improving treatment and lowering cardiovascular risk in T1D.
The NOFO also draws clear boundaries around what it will not fund under this announcement. Studies that are purely observational, general epidemiology projects, and efficacy trials focused mainly on testing whether an intervention works (without a strong mechanistic emphasis) are described as non-responsive. Basic animal research is also non-responsive for this particular solicitation. In practice, that means proposals should avoid being framed as population-level association studies, standard cohort analyses, or standalone randomized trials that primarily measure clinical endpoints without explaining underlying pathways. Instead, applicants should focus on mechanistic human research that can link sleep and circadian disruption to measurable metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in T1D.
Eligibility is broad and includes many standard NIH-eligible applicant types such as state, county, and local governments; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses) and small businesses; independent school districts; special district governments; public housing authorities; and federally recognized tribal governments and other tribal organizations. The announcement explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions (non-U.S. entities) are not eligible to apply as the applicant organization, but non-U.S. components of U.S. organizations are allowed, and foreign components (as NIH defines them) may be included when permitted under NIH policy.
From an administrative standpoint, this is a discretionary grant using the NIH R01 mechanism, with activity in the health domain and CFDA numbers listed as 93.233, 93.837, and 93.838. The original closing date in the provided source data is 2023-10-11, and the listed award ceiling is $420,000 (as provided in the dataset). Overall, the solicitation is best suited for teams proposing hypothesis-driven, mechanistic human studies that directly connect sleep and circadian disruption to the metabolic and cardiovascular complications that shape real-world outcomes in Type 1 Diabetes, with an eye toward actionable pathways that could later support targeted sleep or circadian interventions.Apply for RFA HL 24 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838.
- This funding opportunity was created on 2023-07-20.
- Applicants must submit their applications by 2023-10-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $420,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH RFA-HL-24-008 (R01 Clinical Trial Optional)
What is the full title of this NIH funding opportunity?
The opportunity is RFA-HL-24-008, titled "The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)."
What is the main goal of RFA-HL-24-008?
The main goal is to clarify how sleep deficiency and circadian rhythm disruption influence the biology of Type 1 Diabetes (T1D), particularly in ways that affect glycemic control and cardiovascular risk. The emphasis is on identifying clinically meaningful mechanisms that explain how and why sleep and circadian factors drive metabolic and cardiovascular changes in T1D.
What kinds of research questions is NIH trying to answer through this R01?
NIH is looking for research that moves beyond documenting that sleep problems occur in T1D. Applications should focus on mechanism-focused questions that explain how sleep deficiency and circadian disruption contribute to metabolic and cardiovascular pathobiology, influence disease progression over time, and potentially change how patients respond to treatment.
What does "mechanism-focused" mean in the context of this announcement?
In this announcement, "mechanism-focused" means studies should be designed to uncover biological or physiological pathways linking sleep/circadian disruption to measurable changes in glycemic control and cardiovascular risk in people with T1D. Projects should emphasize "how and why" sleep and circadian factors matter, not just whether they are statistically associated with outcomes.
What is the expected impact or payoff NIH wants from funded projects?
The broader payoff is evidence that can support practical sleep- or circadian-based strategies that improve outcomes for people living with T1D and reduce cardiovascular complications related to the disease.
What type of grant mechanism is being used?
This is a discretionary grant using the NIH R01 mechanism.
Is a clinical trial required under this funding opportunity?
No. The notice is labeled "Clinical Trial Optional," meaning a clinical trial component may be included if scientifically justified, but a clinical trial is not required.
If a project includes human research, what is NIH expecting?
Any human research should be tightly linked to mechanistic questions, with clear relevance to improving treatment and lowering cardiovascular risk in T1D. The research should connect sleep and circadian disruption to measurable metabolic and cardiovascular biology and outcomes that matter clinically.
What kinds of projects are specifically described as non-responsive?
Non-responsive projects include studies that are purely observational, general epidemiology projects, and efficacy trials that mainly test whether an intervention works without a strong mechanistic emphasis. Basic animal research is also non-responsive for this solicitation.
Are purely observational or population-level association studies a fit for this RFA?
No. Proposals framed primarily as population-level association studies, standard cohort analyses, or general epidemiology projects are described as non-responsive under this announcement.
Would a standard randomized trial focused mainly on clinical endpoints be responsive?
Not by itself. Efficacy trials focused mainly on testing whether an intervention works, without strong mechanistic emphasis, are described as non-responsive. Any clinical trial component should be justified by and centered on mechanistic questions tied to sleep/circadian disruption and T1D-related metabolic and cardiovascular biology.
Is basic animal research allowed under this funding opportunity?
No. Basic animal research is described as non-responsive for this particular solicitation.
What scientific areas does NIH expect to be integrated in responsive applications?
Applications are expected to integrate sleep and circadian measurement and biology with endocrinology/diabetes management and cardiovascular phenotyping. The opportunity is designed for work at the intersection of sleep/circadian science, diabetes, and cardiovascular biology.
Does NIH encourage multidisciplinary teams for this R01?
Yes. The announcement emphasizes multidisciplinary expertise, for example combining sleep and circadian measurement/biology with diabetes management and cardiovascular phenotyping to address clinically meaningful mechanistic questions.
Who is eligible to apply as an applicant organization?
Eligibility is broad and includes many standard NIH-eligible applicant types, such as state, county, and local governments; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses) and small businesses; independent school districts; special district governments; public housing authorities; and federally recognized tribal governments and other tribal organizations.
Are minority-serving institutions and community-based organizations eligible?
Yes. The announcement explicitly highlights eligibility for organizations such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Can a foreign (non-U.S.) institution apply as the main applicant?
No. Foreign institutions (non-U.S. entities) are not eligible to apply as the applicant organization.
Are foreign components allowed in any form?
Yes. Non-U.S. components of U.S. organizations are allowed, and foreign components (as NIH defines them) may be included when permitted under NIH policy.
What domain or topic area does this funding opportunity fall under?
The opportunity is in the health domain and focuses on sleep deficiency/circadian disruption in Type 1 Diabetes, with particular attention to glycemic control and cardiovascular risk.
What CFDA numbers are associated with this opportunity?
The CFDA numbers listed are 93.233, 93.837, and 93.838.
What was the original closing date listed in the provided information?
The original closing date in the provided source data is 2023-10-11.
What is the award ceiling listed in the provided dataset?
The listed award ceiling is $420,000 (as provided in the dataset).
What kinds of projects are the best fit for this solicitation?
This solicitation is best suited for hypothesis-driven, mechanistic human studies that directly connect sleep deficiency and circadian disruption to metabolic and cardiovascular complications in Type 1 Diabetes, with an emphasis on pathways that could ultimately support actionable sleep- or circadian-based strategies to improve outcomes and reduce cardiovascular risk.
What should applicants avoid when framing their proposal under this RFA?
Applicants should avoid framing projects as general epidemiology or purely observational association studies, standard cohort analyses, standalone randomized trials centered mainly on clinical endpoints without mechanistic explanation, or basic animal studies. The core requirement is a clinically relevant mechanistic focus in humans.
Browse more opportunities from the same category: Health
Next opportunity: Fiscal Year 2025 Defense University Research Instrumentation Program (DURIP)
Previous opportunity: Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 24 008
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 24 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required) Apply for RFA AG 24 044 Funding Number: RFA AG 24 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Apply for RFA RM 23 015 Funding Number: RFA RM 23 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Supporting Vaccine Confidence Apply for NV VSR 24 001 Funding Number: NV VSR 24 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) Apply for RFA NS 24 024 Funding Number: RFA NS 24 024 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional) Apply for PAR 23 235 Funding Number: PAR 23 235 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Network of Genomics-Enabled Learning Health Systems (gLHS) Coordinating Center (U01 Clinical Trials Required) Apply for RFA HG 23 042 Funding Number: RFA HG 23 042 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| Network of Genomics-Enabled Learning Health Systems (gLHS) Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 23 041 Funding Number: RFA HG 23 041 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) Apply for PAR 23 240 Funding Number: PAR 23 240 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required) Apply for RFA OD 23 021 Funding Number: RFA OD 23 021 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional) Apply for RFA NS 24 026 Funding Number: RFA NS 24 026 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alcohol Health Services Research (R34 Clinical Trial Optional) Apply for PAR 23 252 Funding Number: PAR 23 252 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Alcohol Health Services Research (R01 Clinical Trial Optional) Apply for PAR 23 251 Funding Number: PAR 23 251 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 Clinical Trial Required) Apply for RFA AG 24 045 Funding Number: RFA AG 24 045 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required) Apply for PAR 23 250 Funding Number: PAR 23 250 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required) Apply for PAR 23 249 Funding Number: PAR 23 249 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed) Apply for RFA NS 24 006 Funding Number: RFA NS 24 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD?(R01 Clinical Trial Not Allowed) Apply for RFA AG 24 028 Funding Number: RFA AG 24 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD?(R21 Clinical Trial Not Allowed) Apply for RFA AG 24 029 Funding Number: RFA AG 24 029 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed) Apply for RFA NS 24 007 Funding Number: RFA NS 24 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional) Apply for RFA AG 24 041 Funding Number: RFA AG 24 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 24 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.